Novavax, Inc. (NASDAQ:NVAX) Shares Sold by Federated Hermes Inc.

Federated Hermes Inc. lowered its position in shares of Novavax, Inc. (NASDAQ:NVAX) by 88.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 52,713 shares of the biopharmaceutical company’s stock after selling 409,114 shares during the period. Federated Hermes Inc.’s holdings in Novavax were worth $253,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of NVAX. Vanguard Group Inc. lifted its holdings in Novavax by 9.3% during the 3rd quarter. Vanguard Group Inc. now owns 11,551,476 shares of the biopharmaceutical company’s stock worth $83,633,000 after buying an additional 978,873 shares during the last quarter. TSP Capital Management Group LLC lifted its stake in Novavax by 15.0% during the fourth quarter. TSP Capital Management Group LLC now owns 1,111,700 shares of the biopharmaceutical company’s stock worth $5,336,000 after purchasing an additional 145,350 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Novavax by 7.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 703,350 shares of the biopharmaceutical company’s stock worth $5,092,000 after purchasing an additional 51,274 shares during the last quarter. Rock Springs Capital Management LP boosted its holdings in Novavax by 20.7% in the third quarter. Rock Springs Capital Management LP now owns 647,700 shares of the biopharmaceutical company’s stock valued at $4,689,000 after purchasing an additional 111,000 shares in the last quarter. Finally, Barclays PLC increased its stake in Novavax by 2.3% in the third quarter. Barclays PLC now owns 553,790 shares of the biopharmaceutical company’s stock valued at $4,011,000 after purchasing an additional 12,235 shares during the last quarter. Institutional investors and hedge funds own 53.04% of the company’s stock.

Novavax Stock Performance

Shares of NVAX stock opened at $4.93 on Monday. Novavax, Inc. has a 1 year low of $3.53 and a 1 year high of $11.36. The stock’s 50-day moving average is $4.71 and its two-hundred day moving average is $5.01. The firm has a market cap of $692.17 million, a price-to-earnings ratio of -0.89 and a beta of 1.63.

Novavax (NASDAQ:NVAX) last announced its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($1.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.95). The firm had revenue of $291.34 million for the quarter, compared to analyst estimates of $310.96 million. During the same period last year, the firm earned ($2.28) earnings per share. The business’s revenue was down 18.5% on a year-over-year basis. As a group, research analysts predict that Novavax, Inc. will post -0.82 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reduced their price objective on shares of Novavax from $35.00 to $19.00 and set a “buy” rating for the company in a research report on Friday, March 1st.

Novavax Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.